Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Anderlecht – page 27

433 clinical trials in Anderlecht, Belgium across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Anderlecht at a glance
433
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

433 trials in Anderlecht

Open in trial search

Hepatic cirrhosis

Not recruiting

Study on the Effects of Human Serum Albumin on Survival in Patients with Severe Acute-On-Chronic Liver Failure

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:Instituto Grifols S.A.

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Inhaled Imatinib (AV-101) for Patients with Pulmonary Arterial Hypertension (PAH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Rheumatoid arthritis

Not recruiting

Study on Rosnilimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab
  • Sponsor:Anaptysbio Inc.

Metabolic dysfunction-associated liver disease

Not recruiting

Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Gsk4532990A
  • Sponsor:Glaxosmithkline Research & Development Limited

Pulmonary arterial hypertension

Not recruiting

Long-Term Safety Study of Inhaled Imatinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Aerovate Therapeutics Inc.

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Everolimus
  • Sponsor:Rayzebio Inc.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

K-ras gene mutation+1

Not recruiting

Study of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:ETOP IBCSG Partners Foundation

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Anderlecht

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials investigating new treatments for various cancers, including bladder cancer, acute myeloid leukemia, and advanced breast cancer. Studies focus on innovative combination therapies and targeted treatments.

  • Non-muscle invasive bladder cancer therapy
  • Metastatic breast cancer treatments
  • Gastroesophageal cancer interventions
02 Immunology and Inflammatory Conditions

Clinical investigations targeting chronic inflammatory conditions and autoimmune disorders, including Crohn's Disease, Ulcerative Colitis, and Psoriatic Arthritis.

  • Inflammatory bowel disease therapies
  • Novel arthritis treatments
  • Sjögren's Disease interventions
03 Infectious Diseases

Studies examining innovative approaches to combat various infections, including urinary tract infections and viral diseases. Research includes vaccine development and antimicrobial therapies.

  • UTI vaccine development
  • RSV vaccination studies
  • Hepatitis D treatments
04 Cardiovascular and Pulmonary Studies

Research focusing on pulmonary hypertension and cardiovascular disease management, with emphasis on innovative therapeutic approaches and disease prevention.

  • Pulmonary arterial hypertension treatments
  • Cardiovascular disease interventions
  • Post-cardiac arrest care
Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.